Skip to main content
Skip to content

Duplicate Document

This document appears to be a copy. The original version is:

Legal analysis of marijuana, industrial hemp, and CBD oil under CSA and Farm Bill
Case File
kaggle-ho-024709House Oversight

Legal analysis of marijuana, industrial hemp, and CBD oil under CSA and Farm Bill

Legal analysis of marijuana, industrial hemp, and CBD oil under CSA and Farm Bill The passage provides a technical overview of regulatory distinctions between marijuana, industrial hemp, and CBD oil, without naming any individuals, transactions, or allegations of misconduct. It lacks actionable leads, novel revelations, or connections to powerful actors, making it low-value for investigative purposes. Key insights: Distinguishes CSA controls for non‑industrial hemp vs. industrial hemp.; Notes the Farm Bill's 0.3% THC threshold and its limited exemption scope.; Highlights ambiguity over whether CBD oil qualifies as industrial hemp under the law.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024709
Pages
1
Persons
3
Integrity
No Hash Available

Summary

Legal analysis of marijuana, industrial hemp, and CBD oil under CSA and Farm Bill The passage provides a technical overview of regulatory distinctions between marijuana, industrial hemp, and CBD oil, without naming any individuals, transactions, or allegations of misconduct. It lacks actionable leads, novel revelations, or connections to powerful actors, making it low-value for investigative purposes. Key insights: Distinguishes CSA controls for non‑industrial hemp vs. industrial hemp.; Notes the Farm Bill's 0.3% THC threshold and its limited exemption scope.; Highlights ambiguity over whether CBD oil qualifies as industrial hemp under the law.

Tags

kagglehouse-oversightcannabis-regulationindustrial-hempcbd-oilcontrolled-substances-actfarm-bill

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
CHAPTER IV U.S. Legal Landscape U.S. Legal Relationship between Marijuana and Industrial Hemp Mature stalks; fiber made from mature stalks; oil or cake made from seeds; compounds, Cannabis plant and all parts and manufactures, salts, mixtures, preparations derivatives except non-marijuana or derivatives of the foregoing parts and derivatives (except resin extracted from mature stalks); sterilized seeds Sis- Non-Industrial Hemp « Manufacture, distribution, dispensing « No CSA controls Cannabis plant and all parts and and possession controlled under CSA derivatives except industrial hemp * No Farm Bill exception to CSA * Farm Bill exception to CSA moot Industrial Hemp * Manufacture, distribution, dispensing « No CSA controls and possession controlled under CSA Cannabis plant and any part with THC (but subject to Farm Bill exception) concentration not more than 0.3% on F . . ; ; a dry weight basis « Farm Bill exception to CSA controls: « Farm Bill exception to CSA moot state-legal cultivation by an institution of higher education or a state department of agriculture for research Industrial hemp can be used to produce CBD oil, an extract of the cannabis plant with a high concentration of cannabidiol (CBD) but little or no psychoactive THC. CBD oil is believed to have a range of medicinal benefits and therapeutic applications. Some have argued that the Farm Bill federally legalizes the production and sale of CBD oil. However, it is unclear whether CBD oil produced from industrial hemp is itself considered industrial hemp (the CSA defines marijuana by reference to the cannabis plant, parts of the plant and derivatives of the plant, whereas the Farm Bill exception to the CSA defines industrial hemp by reference only to the plant and parts of the plant, but does not men- tion derivatives). Even if CBD oil is considered industrial hemp and may be lawfully produced under the Farm Bill, only institutions of higher education and state departments of agriculture are authorized to produce it, and then only for purposes of agricultural or academic research; thus the Farm Bill likely does not create a CSA exception broad enough for large-scale commercial production and distribution of CBD oil within the United States. Federal Food, Drug, and Cosmetic Act The Federal Food, Drug, and Cosmetic Act (FD&C Act) is a federal law enacted in 1938 (and since amended multiple times) that authorizes the FDA to regulate the safety and effectiveness of drugs and medical devices and the safety of food, tobacco products and cosmetics. The FD&C Act prohibits the “adulteration or misbranding” of any drug, medical device, food, tobacco product or cosmetic (which the act generally refers to as “articles”) in interstate commerce and prohibits interstate commerce in any such adulterated or misbranded article. The FD&C Act also prohibits the “introduction or delivery for © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 73

Related Documents (6)

House OversightUnknown

Supreme Court Slip Opinion on International Finance Corp. Immunity

Supreme Court Slip Opinion on International Finance Corp. Immunity The passage discusses legal doctrine on international organization immunity without mentioning any wrongdoing, financial misconduct, or high‑profile individuals. It offers no actionable leads, novel allegations, or controversial connections to powerful actors. Key insights: Clarifies that the International Organizations Immunities Act grants IOs the same immunity as foreign governments under FSIA.; Notes the case involves IFC's loan to an Indian coal plant and plaintiffs' environmental claims.; Affirms lower court's dismissal based on immunity doctrine.

1p
House OversightOtherNov 11, 2025

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct

The passage is a regulatory notice from the National Labor Relations Board discussing draft language on union rights and employer conduct. It contains no specific allegations, financial flows, or link Comments from the Heritage Foundation and National Immigration Law Center propose additions to the N The Board rejects suggestions to expand the notice with specific employer retaliation examples. Di

3p
House OversightUnknown

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct The passage is a regulatory notice from the National Labor Relations Board discussing draft language on union rights and employer conduct. It contains no specific allegations, financial flows, or links to high‑profile officials or entities. The only potential leads are generic references to comments from interest groups (Heritage Foundation, National Immigration Law Center) but they do not provide actionable evidence of misconduct. Key insights: Comments from the Heritage Foundation and National Immigration Law Center propose additions to the NLRB notice.; The Board rejects suggestions to expand the notice with specific employer retaliation examples.; Discussion of “special circumstances” for prohibiting union insignia and clarification on spying/videotaping rules.

1p
House OversightFeb 26, 2019

Cowen CBD Market Outlook Report – No Evident Investigative Leads

Cowen CBD Market Outlook Report – No Evident Investigative Leads The document is a commercial research note on CBD market size and analyst ratings, containing no references to political figures, financial misconduct, or intelligence activities. It offers no actionable investigative leads. Key insights: Provides market size estimate for U.S. CBD ($16 bn by 2025).; Cites a proprietary survey showing 7% adult usage.; Mentions analyst ratings for WEED, TLRY, TPB.

1p
House OversightUnknown

Deep Thinking – collection of essays by AI thought leaders

Deep Thinking – collection of essays by AI thought leaders The document is a largely philosophical and historical overview of AI research, its thinkers, and societal implications. It contains no concrete allegations, financial transactions, or novel claims that point to actionable investigative leads involving influential actors. The content is primarily a synthesis of known public positions and historical anecdotes, offering limited new information for investigative follow‑up. Key insights: Highlights concerns about AI risk and alignment voiced by prominent researchers (e.g., Stuart Russell, Max Tegmark, Jaan Tallinn).; Notes the growing corporate influence on AI development (e.g., references to Google, Microsoft, Amazon, DeepMind).; Mentions historical episodes where AI research intersected with military funding and government secrecy.

1p
House OversightApr 28, 2015

Book blurb on Alan Turing, free will, and James Tagg's bio

Book blurb on Alan Turing, free will, and James Tagg's bio The document contains no actionable investigative leads, no mention of powerful officials, financial transactions, or wrongdoing. It is a promotional text about historical topics and an entrepreneur’s background, offering no novel or controversial information. Key insights: Discusses Alan Turing’s historical contributions; Poses philosophical questions about AI and free will; Provides a brief biography of James Tagg, a tech entrepreneur

1p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.